• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA: DPP-4 diabetes drugs may be harmful

FDA: DPP-4 diabetes drugs may be harmful

August 31, 2015
CenterWatch Staff

DPP-4 diabetes drugs might cause “severe and disabling” joint pain, according to a new warning issued by the FDA.

Research by the agency’s drug safety team has turned up cases of severe joint pain in patients using DPP-4 inhibitors to control their blood sugar. In its drug safety communication, the FDA said the symptoms sometimes were immediate, but at other times surfaced years after a patient started taking one of the drugs.

After the drugs were discontinued, the patients’ symptoms stopped, generally in less than 30 days. Some patients saw the pain return after they restarted the same product or switched to a different DPP-4 drug.

The FDA’s joint-pain warning was added to the official labeling on the entire DPP-4 class. The most popular DPP-4 meds are Merck & Co.’s Januvia products and two Januvia-plus-metformin products that are sold under the Janumet brand. The class also includes AstraZeneca’s Onglyza (saxagliptin) and its metformin combo Kombiglyze; Eli Lilly and Boehringer Ingelheim’s Tradjenta (linagliptin) and related combos Glyxambi and Jentadueto; and the newest entry, Takeda's Nesina (alogliptin), and two combo pills, Kazano and Oseni.

The FDA has added warnings to the meds in the past. The entire DPP-4 class already carries cautionary language about the risk of pancreatitis and allergic reactions, in addition to hypoglycemia when used in combination with other diabetes meds.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing